Updates are available Correction dated 2026-02-04
Click to view Correction: https://doi.org/10.1038/s41556-026-01897-w
-
Authors
Zhang, Yutong
Hu, Meiqin https://orcid.org/0000-0002-3953-5868
Meng, Yaping
Wang, Xin
Huang, Fangqian
Li, Ping
Zhuo, Yuting
Chen, Danzhen
Wang, Zhimin
Zhang, Qiang https://orcid.org/0009-0002-6595-1715
Wu, Hui
He, Yao
Du, Yulin
Xu, Haoxing https://orcid.org/0000-0003-3561-4654
Qiu, Liping https://orcid.org/0000-0001-7612-2627
Tan, Weihong https://orcid.org/0000-0002-8066-1524
- License Information
-
More Information
Article History
Received: 26 March 2025
Accepted: 11 December 2025
First Online: 21 January 2026
Change Date: 4 February 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41556-026-01897-w
Competing interests
: H.X. is the scientific cofounder and a partial owner of Lysoway Therapeutics Inc. (Boston) and Lyso-X Therapeutics Inc. (Hangzhou). The other authors declare no competing financial interests.
